Showing results (11-20 of 451) with videos related to

Sort By:
Pageof 46
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigensC Castelli, P Tarsini, A Mazzocchi, et al.
International Journal of Cancer|May 15, 1989
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistanceL Rivoltini, C Gambacorti-Passerini, R Supino, et al.
Experimental and Clinical Immunogenetics|January 1, 1991
Recombinant interferon-gamma differently affects DQA and DRA gene expression in two human melanoma clones: transcriptional and posttranscriptional regulationC Castelli, M Sensi, G Parmiani
Melanoma Research|August 1, 1997
New tumour-restricted melanoma antigens as defined by cytotoxic T-cell responsesG Parmiani, A Anichini, C Castelli
Cancer Research|June 11, 1998
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35)D J Loftus, P Squarcina, M B Nielsen, et al.
The International Journal of Biological Markers|July 1, 1992
CEA and NCA expressed by colon carcinoma cells affect their interaction with and lysability by activated lymphocytesL Rivoltini, G Cattoretti, F Arienti, et al.
Cancer Research|February 2, 1999
A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapyL Rivoltini, P Squarcina, D J Loftus, et al.
The Journal of Experimental Medicine|August 1, 1996
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)D J Loftus, C Castelli, T M Clay, et al.
The Journal of Experimental Medicine|August 4, 1999
Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cellsZ Wang, F M Marincola, L Rivoltini, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1993
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cellsP A Ruffini, L Rivoltini, A Silvani, et al.
Pageof 46